Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4179-4183

  Schulten, Hans Juergen ^a   Al Maghrabi, Jaudah ^b,c   Al Ghamdi, Khalid ^c   Salama, Sherine ^b   Al Muhayawi, Saad ^b   Chaudhary, Adeel ^a   Hamour, Osman ^c   Abuzenadah, Adel ^a   Gari, Mamdooh ^a   Al Qahtani, Mohammed ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

AKT1; BRAE; CTNNB1; Gene mutations; HRAS; KRAS; Medullary thyroid carcinoma; Mutational screening; NRAS; RET

Indexed keywords

B RAF KINASE; BETA CATENIN; GENOMIC DNA; H RAS PROTEIN; ONCOPROTEIN; PROTEIN AKT 1; PROTEIN RET; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; CODON; CONTROLLED STUDY; EXON; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INHERITANCE; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; ONCOGENE H RAS; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEQUENCE ANALYSIS; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

ADULT; AGED; BETA CATENIN; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; ONCOGENE PROTEIN P21(RAS); PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 84855168481     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM Stewart AK and Hoelzer S: Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 89: 202-217, 2000. (Pubitemid 30451292)
2. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F and Pinchera A: Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93: 682-687, 2008. (Pubitemid 351398539)
3. Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO, Bugalho MJ and Leite V: Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 100: 1777-1783, 2009.
4. de Groot JW, Links TP, Plukker JT, Lips CJ and Hofstra RM: RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 27: 535-560, 2006. (Pubitemid 44213230)
5. Romei C, Cosci B, Renzini G, Bottici V, Molinaro E, Agate L, Passannanti P, Viola D, Biagini A, Basolo F, Ugolini C, Materazzi G, Pinchera A, Vitti P and Elisei R: RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clin Endocrinol (Oxf) 74: 241-247, 2011.
6. Muzza M, Cordella D, Bombled J, Bressac-de Paillerets B, Guizzardi F, Francis Z, Beck-Peccoz P, Schlumberger M, Persani L and Fugazzola L: Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro. Eur J Endocrinol 162: 771-777, 2010.
7. Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, Ryska A, Laco J, Cap J, Kodetova D, Kodet R, Krskova L, Vlcek P, Astl J, Vesely D and Bendlova B: Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 284: 21-27, 2008.
8. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M and Wells SA Jr.: Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19: 565-612, 2009.
9. Sippel RS, Kunnimalaiyaan M and Chen H: Current management of medullary thyroid cancer. Oncologist 13: 539-547, 2008. (Pubitemid 351872871)
10. Emison ES, Garcia-Barcelo M, Grice EA, Lantieri F, Amiel J, Burzynski G, Fernandez RM, Hao L, Kashuk C, West K, Miao X, Tam PK, Griseri P, Ceccherini I, Pelet A, Jannot AS, de Pontual L, Henrion-Caude A, Lyonnet S, Verheij JB, Hofstra RM, Antiñolo G, Borrego S, McCallion AS and Chakravarti A: Differential contributions of rare and common, coding and noncoding RET mutations to multifactorial Hirschsprung disease liability. Am J Hum Genet 87: 60-74, 2010.
11. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK and Wells SA Jr.: Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353: 1105-1113, 2005. (Pubitemid 41317433)
12. Nikiforov YE: Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21(Suppl 2): S37-43, 2008.
13. Fernández-Medarde A and Santos E: RAS in cancer and developmental diseases. Genes Cancer 2: 344-358, 2011.
14. Shinohara M, Chung YJ, Saji M and Ringel MD: AKT in thyroid tumorigenesis and progression. Endocrinology 148: 942-947, 2007.
15. Abbosh PH and Nephew KP: Multiple signaling pathways converge on beta-catenin in thyroid cancer. Thyroid 15: 551-561, 2005. (Pubitemid 40993728)
16. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL and Thomas JE: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-444, 2007. (Pubitemid 47123510)
17. Rapa I, Saggiorato E, Giachino D, Palestini N, Orlandi F, Papotti M and Volante M: Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. J Clin Endocrinol Metab 96: 2146-2153, 2011.
18. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL and Tallini G: Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158: 987-996, 2001. (Pubitemid 32221790)
19. Ahmed M, Al-Saihati B, Greer W, Al-Nuaim A, Bakheet S, Abdulkareem AM, Ingemansson S, Akhtar M and Ali MA: A study of 875 cases of thyroid cancer observed over a fifteen-year period (1975-1989) at the King Faisal Specialist Hospital and Research Centre. Ann Saudi Med 15: 579-584, 1995. (Pubitemid 26014417)
20. Qari FA: Pattern of thyroid malignancy at a University Hospital in Western Saudi Arabia. Saudi Med J 25: 866-870, 2004.
21. DeLellis RA and Williams ED. Thyroid and parathyroid tumors. In: Pathology and Genetics of Tumours of Endocrine Organs. IARC WHO Classification of Tumours. DeLellis RA, Lloyd RV, Heitz PU and Eng C (eds.). Lyons, France: IARC Press, pp. 51-56, 2004.
22. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A (eds.). AJCC Cancer Staging Manual. 7th edition. New York, NY, USA: Springer, pp. 87-96, 2010.
23. Santoro M, Melillo RM, Carlomagno F, Visconti R, De Vita G, Salvatore G, Lupoli G, Fusco A and Vecchio G: Molecular biology of the MEN2 gene. J Intern Med 243: 505-508, 1998. (Pubitemid 28312248)
24. Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, Toledo SP, Toledo RA, Tavares MR, Alevizaki M, Mian C, Siggelkow H, Hüfner M, Wohllk N, Opocher G, Dvořáková S, Bendlova B, Czetwertynska M, Skasko E, Barontini M, Sanso G, Vorländer C, Maia AL, Patocs A, Links TP, de Groot JW, Kerstens MN, Valk GD, Miehle K, Musholt TJ, Biarnes J, Damjanovic S, Muresan M, Wüster C, Fassnacht M, Peczkowska M, Fauth C, Golcher H, Walter MA, Pichl J, Raue F, Eng C, Neumann HP; International RET Exon 10 Consortium: Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat 32: 51-58, 2011.
25. Vitagliano D, De Falco V, Tamburrino A, Coluzzi S, Troncone G, Chiappetta G, Ciardiello F, Tortora G, Fagin J, Ryan AJ, Carlomagno F and Santoro M: The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer 18: 1-11, 2010.
26. Verbeek HH, Alves MM, de Groot JW, Osinga J, Plukker JT, Links TP and Hofstra RM: The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 96: E991-995, 2011.
27. Moura MM, Cavaco BM, Pinto AE and Leite V: High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 96: E863-868, 2011.
28. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE and Sherman SI: Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27: 3794-3801, 2009.